拉米夫定联合水飞蓟滨治疗乙肝肝硬化临床观察

Effects of lamivudine combining with silybin on secondary cirrhosis induced by hepatitis B

目的:探讨拉米夫定联合水飞蓟滨对乙型肝炎肝硬化指标变化的影响。方法:将64例乙型肝炎肝硬化患者随机分为治疗组和对照组,治疗最少12个月,在治疗前、治疗后半年及治疗前、治疗后12个月测定肝纤维化指标及肝功能指标,进行相关性比较分析。结果:治疗组肝纤维化及肝功能指标下降明显优于对照组(P<0.05);同时其AST治疗组1年后与半年后比较AST下降明显,其疗效与疗程呈相关性。结论:拉米夫定联合水飞蓟滨能明显降改善乙肝肝硬化患者肝纤维化指标及肝功能指标。

Objective To investigate the influence of lamivudine combining with silibin on major in- dicators of liver cirrhosis in patients with hepatitis B. Methods A total of 64 patients with liver cirrhosis induced by hepatitis B were randomly divided into treatment group and control group and were treated for at least 12 months. Before treatment, half a year after treatment, 12 months before and after treatment, major indicators of cirrhosis and liver function were analyzed and compared. Results. The treatment group showed significant obvious improvements in major indicators of cirrhosis and liver function compared with the control group （P〈0.05）. Besides, decrease in AST level 1 year before and after the treatment of the treatment group was also more obvious, and the decrease was correlated with treatment course. Conclusions.. Lamivudine combining with silibinin can significantly improve the hepatic fibrosis and liver function indicators in patients cirrhosis induced by hepatitis B